title: Nebulized terbutaline and positive expiratory pressure in chronic obstructive pulmonary disease.
abstract: The effect of positive expiratory pressure (PEP) and inhaled terbutaline was evaluated in ten patients with chronic obstructive pulmonary disease in a randomized cross-over study with three 2 weeks periods. In one period 5 mg terbutaline was inhaled 3 times daily from a nebulizer combined with PEP. In a second period 5 mg terbutaline was inhaled similarly but without PEP and in a third period placebo inhalations were combined with PEP. Symptom score and peak expiratory flow (PEF) measured before and after each inhalation was noted in a diary. The treatment with nebulized terbutaline combined with PEP gave the best relief in symptoms. All treatments increased PEF significantly. PEP alone gave the least increase in PEF (25 1/min), and there was no difference between the increase in PEF after terbutaline inhaled with PEP (28 1/min) compared to terbutaline alone (29 1/min).
authors.affiliation: Department of Respiratory Diseases, University Hospital of Aarhus, Denmark.
authors.forename: E F
authors.initials: EF
authors.lastname: Christensen
authors.forename: O
authors.initials: O
authors.lastname: Nørregaard
authors.forename: R
authors.initials: R
authors.lastname: Dahl
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D010366:Peak Expiratory Flow Rate; D011175:Positive-Pressure Respiration / Q000379:methods*; D013726:Terbutaline / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D013726:Terbutaline